Retrospective review of the clinical and laboratory data in silent lupus nephritis

Basit Öğe Kaydı
dc.authorscopusid56891696300
dc.authorscopusid25629707900
dc.authorscopusid6603074949
dc.authorwosidYargucu Zihni, Figen/AAA-5814-2022
dc.contributor.authorZihni, Figen Yargucu
dc.contributor.authorKarabulut, Gonca
dc.contributor.authorOksel, Fahrettin
dc.date.accessioned2023-01-12T19:50:52Z
dc.date.available2023-01-12T19:50:52Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractPurpose To determine the ratio of renal disease necessitating immunosuppressive treatment in lupus patients who are clinically asymptomatic by means of renal disease. It was also examined whether silent lupus nephritis is associated with any of the non-renal clinical findings. Methods All kidney biopsies performed in lupus patients between 1990 and 2009 at the Rheumatology Department of Ege University Faculty of Medicine were retrospectively screened. Among the 258 kidney biopsies screened, 54 had no clinical renal findings but had active disease together with anti-dsDNA positivity and/or hypocomplementemia. Patients were classified into two groups who require and do not require immunosuppressive therapy according to their final pathological results at biopsy. The frequency of serious renal involvement in the sample was calculated. Then subgroups were compared with each other in terms of the clinical and laboratory features using Statistical Package for Social Sciences version 13 software. Results Thirteen of the 54 patients (24%) had severe renal involvement requiring immunosuppressant therapy. When the groups were compared to each other, it was found that serositis and hematologic involvement were significantly more frequent in patients who needed immunosuppressive treatment (42.9% versus 10.0%; p = 0.003 and 64.3% versus 37.5; p = 0.039). Conclusion Even in the absence of clinical renal manifestations, active patients at high risk of renal disease such as hypocomplementemia, anti-ds DNA positivity may have severe renal disease requiring immunosuppressive treatment. Thus, renal biopsy indications in lupus patients should better be revaluated.en_US
dc.identifier.doi10.1007/s11255-021-03066-4
dc.identifier.endpage1938en_US
dc.identifier.issn0301-1623
dc.identifier.issn1573-2584
dc.identifier.issue8en_US
dc.identifier.pmid34853989en_US
dc.identifier.scopus2-s2.0-85120428308en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1933en_US
dc.identifier.urihttps://doi.org/10.1007/s11255-021-03066-4
dc.identifier.urihttps://hdl.handle.net/11454/76187
dc.identifier.volume54en_US
dc.identifier.wosWOS:000724636200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Urology and Nephrologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSystemic lupus erythematosusen_US
dc.subjectKidney biopsyen_US
dc.subjectLupus nephritisen_US
dc.subjectSilent lupus nephritisen_US
dc.subjectRenal Involvementen_US
dc.subjectErythematosusen_US
dc.subjectBiopsyen_US
dc.subjectDiseaseen_US
dc.subjectClassificationen_US
dc.subjectPredictorsen_US
dc.titleRetrospective review of the clinical and laboratory data in silent lupus nephritisen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu